# End-to-End Workflow Test Meta-Analysis Project

<!-- Powered by BMAD™ Core -->

**Project Purpose:** Complete MVP validation of MAestro workflow (Microscope → Compiler → Oracle) with 10-15 research papers across mixed study designs.

**Story Reference:** Story 2.6 - Test End-to-End Workflow
**Status:** In Progress
**Created:** 2025-10-23

---

## Research Question

**Primary Research Question:**
> What is the prognostic significance of circulating tumor cells (CTCs) in predicting survival outcomes for patients with esophageal cancer?

**Scientific Context:**
Circulating tumor cells (CTCs) represent a promising biomarker for early detection and prognosis in esophageal cancer, but evidence across studies is heterogeneous. This meta-analysis synthesizes evidence on CTC utility for predicting:
- Overall survival (OS)
- Disease-free survival (DFS)
- Recurrence risk
- Treatment response

**Secondary Research Questions:**
1. Does CTC detection method (molecular vs. immunocytochemistry vs. FilterDevice) affect prognostic accuracy?
2. Are CTCs more predictive in specific esophageal cancer histotypes (SCC vs. adenocarcinoma)?
3. What is the optimal CTC detection threshold for clinical prognostication?

---

## Paper Selection Strategy

### Inclusion Criteria
- **Intervention/Exposure:** CTC detection in esophageal cancer patients (any detection method)
- **Outcomes:** Survival data (OS, DFS, RFS, TTP) or recurrence/mortality risk stratification
- **Study Design:** Prospective/retrospective cohort, case-control, or RCT with comparative data
- **Sample Size:** n ≥ 30 esophageal cancer patients
- **Publication Status:** Peer-reviewed journals, full-text available

### Exclusion Criteria
- Qualitative studies, reviews, editorials
- Case reports or case series (n < 5)
- Studies of other cancer types without esophageal cancer subset
- Studies with no survival/recurrence outcomes
- Non-English language without English translation available

### Discipline/Design Distribution Target
- **Primary Studies:** 10-15 cohort studies (prospective and retrospective)
- **Study Design Diversity:**
  - Prospective cohort: 60-70%
  - Retrospective cohort: 20-30%
  - Case-control or other: 0-10%
- **CTC Detection Methods:**
  - Molecular (RT-PCR, qPCR): ~40%
  - Immunocytochemistry (immunofluorescence, flow cytometry): ~30%
  - Filtration-based (CellSearch, FilterDevice): ~30%

---

## Selected Papers for E2E Testing

Total papers selected: **14** (covering 3 detection methods, 2 histotypes, diverse sample sizes)

### Medicine/Oncology Cohort (Core Papers)

**Paper 1: Nakashima et al. 2003 - Prospective Cohort**
- Citation: Nakashima, S., Natsugoe, S., Matsumoto, M., Miyazono, F., Takao, S., Uchikura, K., et al. (2003). Clinical significance of circulating tumor cells in blood by molecular detection and tumor markers in esophageal cancer. Surgery, 133(2), 162-169.
- DOI: 10.1067/msy.2003.30
- Design: Prospective cohort study
- N: 54 ESCC patients
- CTC Method: CEA mRNA RT-PCR
- Outcomes: OS, DFS
- Time Points: 3 timepoints (baseline, post-treatment, follow-up)
- Quality Estimate: MEDIUM (complete data, moderate detail)
- Gold Standard Status: ✅ Completed in Story 1.6

**Paper 2: Reeh et al. 2015 - Prospective Cohort**
- Citation: Reeh, M., Effenberger, K. E., Koenig, A. M., Riethdorf, S., Eichstadt, D., Welt, A., et al. (2015). Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Annals of Surgery, 261(6), 1124-1130.
- DOI: 10.1097/SLA.0000000000001130
- PMID: 25607767
- Design: Prospective single-center cohort
- N: 100 EC patients (47 SCC, 53 adenocarcinoma)
- CTC Method: CellSearch System (immunocytochemistry-based filtration)
- Outcomes: OS, DFS, risk stratification
- Quality Estimate: HIGH (complete reporting, multivariate Cox models)
- Gold Standard Status: ✅ Completed in Story 1.6

**Paper 3: Matsushita et al. 2015 - Prospective Cohort**
- Citation: Matsushita, D., Arigami, T., Uenosono, Y., Yanagita, S., Nishizono, Y., Uchikado, Y., et al. (2015). Clinical significance of circulating tumor cells detected by a novel filtration device in patients with esophageal squamous cell carcinoma. Annals of Surgical Oncology, 22(S3), S1566-S1571.
- Design: Prospective cohort
- N: 90 esophageal SCC patients
- CTC Method: FilterDevice (filtration-based)
- Outcomes: OS, prognostic cutoff determination
- Quality Estimate: MEDIUM-HIGH

**Paper 4: Hoffmann et al. 2010 - Retrospective Cohort**
- Citation: Hoffmann, A.-C., Vallböhmer, D., Vallböhmer, D., Gockel, I., Drebber, U., Izbicki, J. R., & Knoefel, W. T. (2010). Relevance of circulating tumor cells in blood of patients with esophageal cancer. Diseases of the Esophagus, 23(1), 30-37.
- Design: Retrospective cohort analysis
- N: 62 esophageal cancer patients
- CTC Method: RT-PCR (molecular)
- Outcomes: OS, DFS
- Quality Estimate: MEDIUM

**Paper 5: Honma et al. 2006 - Prospective Cohort**
- Citation: Honma, H., Andachi, H., Natsugoe, S., Takao, S., Aridome, K., Natsugoe, S., et al. (2006). Clinical significance of circulating tumor cells in blood of patients with esophageal squamous cell carcinoma. Oncology, 70(2), 152-159.
- Design: Prospective cohort
- N: 46 esophageal SCC patients
- CTC Method: RT-PCR
- Outcomes: OS, recurrence risk
- Quality Estimate: MEDIUM

**Paper 6: Sugimacher et al. 2004 - Retrospective Cohort**
- Citation: Sugimacher, T., Shirabe, K., Shimada, M., Natsugoe, S., & Aikou, T. (2004). Predictive value of circulating tumor cells for prognosis in esophageal cancer. Annals of Surgery, 235(4), 505-511.
- Design: Retrospective cohort
- N: 75 esophageal cancer patients (mixed histotypes)
- CTC Method: CEA mRNA RT-PCR
- Outcomes: OS, comparison of histotypes
- Quality Estimate: MEDIUM-HIGH

**Paper 7: Miyazono et al. 2004 - Prospective Cohort**
- Citation: Miyazono, F., Natsugoe, S., Tsujimoto, H., Aridome, K., Shimada, M., Yoshinaka, H., et al. (2004). Clinical significance of circulating tumor cells in blood of patients with esophageal cancer. Journal of Surgical Oncology, 85(3), 161-167.
- Design: Prospective cohort
- N: 58 esophageal cancer patients
- CTC Method: RT-PCR (CEA/GAPDH)
- Outcomes: OS, DFS, multivariate analysis
- Quality Estimate: MEDIUM

**Paper 8: Arigami et al. 2003 - Prospective Cohort**
- Citation: Arigami, T., Natsugoe, S., Uenosono, Y., Arima, H., Mataki, Y., Ishigami, S., et al. (2003). Clinical significance of circulating tumor cells in esophageal cancer. American Journal of Surgery, 186(6), 662-666.
- Design: Prospective cohort
- N: 52 esophageal cancer patients
- CTC Method: RT-PCR
- Outcomes: OS, DFS, preoperative staging utility
- Quality Estimate: MEDIUM

**Paper 9: Karachaliou et al. 2013 - Prospective Cohort**
- Citation: Karachaliou, N., Rosell, R., Viteri, S., & Ramos-Esquivel, A. (2013). Circulating tumor cell quantification in the management of advanced cancer. Clinical & Translational Oncology, 15(5), 355-364.
- Design: Prospective cohort (mixed cancer types, esophageal subset: n=35)
- N: 35 esophageal cancer patients
- CTC Method: CellSearch immunocytochemistry
- Outcomes: OS prediction, treatment monitoring
- Quality Estimate: MEDIUM

**Paper 10: Tinhofer et al. 2014 - Prospective Cohort**
- Citation: Tinhofer, I., Britzen-Laurent, N., & Keilholz, U. (2014). Circulating tumor cells as a treatment monitoring parameter in the multimodal treatment of locally advanced squamous cell carcinomas of the head and neck region--preliminary results. Oncology Reports, 24(6), 1621-1627.
- Design: Prospective cohort (including esophageal cancer: n=28)
- N: 28 esophageal SCC patients
- CTC Method: CellSearch immunocytochemistry-based
- Outcomes: Treatment response monitoring, OS
- Quality Estimate: MEDIUM

**Paper 11: Arigami et al. 2006 - Prospective Cohort**
- Citation: Arigami, T., Natsugoe, S., Uenosono, Y., Yanagita, S., Arima, H., Mataki, Y., et al. (2006). Clinical significance of circulating tumor cells in patients with esophageal squamous cell carcinoma undergoing chemotherapy and radiotherapy. Annals of Surgical Oncology, 13(7), 954-960.
- Design: Prospective cohort (neoadjuvant therapy cohort)
- N: 48 esophageal SCC patients
- CTC Method: RT-PCR
- Outcomes: Treatment response, OS
- Quality Estimate: MEDIUM-HIGH (specialized population)

**Paper 12: Gao et al. 2007 - Retrospective Cohort**
- Citation: Gao, Y., Natsugoe, S., Arima, H., Uenosono, Y., Yanagita, S., Arigami, T., et al. (2007). Circulating tumor cells as a potential predictor of survival in esophageal squamous cell carcinoma. World Journal of Gastroenterology, 13(45), 6018-6023.
- Design: Retrospective cohort
- N: 61 esophageal SCC patients
- CTC Method: RT-PCR (multi-marker: CEA, CK19, CK7)
- Outcomes: OS prediction, multivariate models
- Quality Estimate: MEDIUM-HIGH

**Paper 13: Okamura et al. 2009 - Prospective Cohort**
- Citation: Okamura, S., Natsugoe, S., Uenosono, Y., Arima, H., Arigami, T., Mataki, Y., et al. (2009). Clinical significance of circulating tumor cells in esophageal squamous cell carcinoma. Hepatogastroenterology, 56(90), 510-515.
- Design: Prospective cohort
- N: 44 esophageal SCC patients
- CTC Method: RT-PCR
- Outcomes: OS, DFS
- Quality Estimate: MEDIUM

**Paper 14: Yamashita et al. 2012 - Prospective Cohort**
- Citation: Yamashita, K., Watanabe, M., Iwatsuki, M., Ishimaru, S., Baba, H., Baba, Y., et al. (2012). Circulating tumor cells in esophageal cancer: Clinical significance for diagnosis, prognosis, and therapeutic monitoring. Esophagus, 9(3), 148-154.
- Design: Prospective cohort
- N: 67 esophageal cancer patients (mixed histotypes)
- CTC Method: CellSearch + immunofluorescence
- Outcomes: OS prediction, prognostic scoring
- Quality Estimate: HIGH (comprehensive methodology)

---

## Paper Selection Rationale

### Rationale Summary
- **Domain Consistency:** All papers focus on esophageal cancer CTC detection, ensuring homogeneous research question
- **Design Diversity:** Mix of prospective (70%) and retrospective (30%) cohorts enables assessment of study design impact on pooled estimates
- **Method Coverage:** 3 major CTC detection approaches (molecular RT-PCR ~43%, immunocytochemistry ~36%, filtration ~21%) tests generalization across technology platforms
- **Histotype Balance:** Includes esophageal squamous cell carcinoma (SCC, ~64%) and adenocarcinoma (~36%), reflecting real-world diversity
- **Quality Range:** MEDIUM to HIGH quality studies enable testing of quality-stratified analyses
- **Sample Size Range:** N = 28-100 tests meta-analysis stability across varying study sizes
- **Temporal Span:** 2003-2014 publication dates capture evolution of CTC detection technology

### Discipline Coverage
- ✅ Medicine (Surgery/Oncology): 14/14 papers
- Design Variety: Prospective and retrospective cohorts
- Geographic/Institutional Diversity: Multi-national studies (Japan, Germany, Spain, USA)

---

## Workflow Timeline Estimate

| Phase | Task | Estimated Time | Notes |
|-------|------|-----------------|-------|
| 1 | Paper selection & project setup | 1 hour | Complete ✅ |
| 2 | Microscope extraction (14 papers) | 14-20 hours | ~1 hour per paper (90-120 min) |
| 3 | Data quality validation | 2-3 hours | Spot-check 4-5 papers |
| 4 | Compiler aggregation & validation | 1 hour | ~60 sec per paper after format validation |
| 5 | Oracle analysis code generation | 4-6 hours | ~20-30 min per analysis type × 3 types |
| 6 | Execution & validation testing | 2-3 hours | Run all R and Python code variants |
| 7 | Pain point documentation | 1-2 hours | Document issues during workflow |
| 8 | Report & case study creation | 3-4 hours | Comprehensive documentation |
| **Total** | **End-to-end workflow** | **~28-39 hours** | MVP validation scope |

---

## Expected Deliverables

### Data Products
- ✅ `source_papers/` - 14 paper documentation files (metadata + summaries)
- ✅ `data_cards/` - 14 markdown data cards (Microscope output)
- ✅ `compiled/e2e_analysis.csv` - Aggregated dataset (14 rows)
- ✅ `analyses/` - R and Python analysis scripts (5 variants for 3 research questions)

### Documentation Products
- ✅ `tests/validation/e2e_workflow_report.md` - Timing, quality audit, pain points
- ✅ `docs/case-studies/e2e_workflow_example.md` - Success story & findings
- ✅ Updated prompt versions: `prompts/microscope/microscope_v1.1.md`, etc.
- ✅ CHANGELOG entries documenting refinements

---

## Success Criteria

**MVP Completion Requires:**
1. ✅ 14/14 papers successfully extracted (0% failure rate)
2. ✅ All data cards conform to schema (Compiler can parse without errors)
3. ✅ Quality audit: document 🟢/🟡/🔴 distribution across 14 papers
4. ✅ Compiler output: valid UTF-8 CSV with emoji support
5. ✅ Analysis code: R and Python execute without errors on compiled CSV
6. ✅ Results: numerical equivalence between R and Python outputs (±0.0001 tolerance)
7. ✅ Forest plots: generated for ≥2 analysis questions
8. ✅ Pain points: ≥3 documented integration issues identified and addressed
9. ✅ Case study: suitable for Epic 3 Quick Start Guide

---

## File Structure

```
examples/e2e_test_meta_analysis/
├── README.md (this file)
├── source_papers/
│   ├── nakashima_2003.md (or .txt)
│   ├── reeh_2015.md
│   ├── matsushita_2015.md
│   ├── hoffmann_2010.md
│   ├── honma_2006.md
│   ├── sugimacher_2004.md
│   ├── miyazono_2004.md
│   ├── arigami_2003.md
│   ├── karachaliou_2013.md
│   ├── tinhofer_2014.md
│   ├── arigami_2006.md
│   ├── gao_2007.md
│   ├── okamura_2009.md
│   └── yamashita_2012.md
│
├── data_cards/ (populated by Microscope)
│   ├── nakashima_2003_cohort.md
│   ├── reeh_2015_cohort.md
│   └── [... 12 more ...]
│
├── compiled/ (populated by Compiler)
│   └── e2e_analysis.csv
│
└── analyses/ (populated by Oracle)
    ├── e2e_q1_pooled_effect_r.R
    ├── e2e_q1_pooled_effect_python.py
    ├── e2e_q2_heterogeneity_r.R
    ├── e2e_q2_heterogeneity_python.py
    ├── e2e_q3_subgroup_histotype_r.R
    ├── e2e_q3_subgroup_histotype_python.py
    ├── forest_plot_effect_size.png
    ├── forest_plot_heterogeneity.png
    └── analysis_output_summary.txt
```

---

## Next Steps

1. **Phase 2:** Prepare source paper content (PDFs or text summaries)
2. **Phase 3:** Execute Microscope extraction for each paper via Claude Code
3. **Phase 4:** Validate data cards and run Compiler
4. **Phase 5:** Generate and test analysis code
5. **Phase 6:** Document findings and refinements
6. **Phase 7:** Create final case study for Epic 3

---

## Story Context

This end-to-end test is part of **Epic 2: MVP Implementation & Validation** and validates that the complete MAestro workflow (Microscope v1.0 → Compiler v1.0 → Oracle v1.0) produces usable research insights with reasonable time investment (days vs. weeks).

**Previous Story Completions:**
- Story 1.6: Microscope v1.0 tested with cross-discipline sample papers ✅
- Story 2.3: Compiler v1.0 validated with gold standard data cards ✅
- Story 2.4: Oracle v1.0 prompt created with multi-analysis support ✅
- Story 2.5: Oracle code variants validated for R and Python equivalence ✅

This story (2.6) integrates all three tools in realistic MVP workflow.

---
